TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
Portfolio Pulse from
TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025, with promising patient enrollment trends.
March 14, 2025 | 6:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass the $525M goal for FY 2025.
The strong buy rating and high price target indicate positive market sentiment. Briumvi's sales exceeding forecasts and the potential for further growth through trials and label updates suggest a strong outlook for TGTX.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100